Current Oncology, Volume 19, Issue 1

The systemic treatment options and algorithm for stage iv non-small-cell lung cancer have changed tremendously since 2005, leading to improved survival and quality of life for this group of patients [...]

Recent studies of cells in culture and of mice models support the notion that the mammary stem cell is a precursor to the breast cancer cell 1–4. [...]

Cancer and non-communicable diseases (ncds) sharing common causal risk factors are not under control [...]

The term “cancer survivor” has been used to convey various meanings over time. [...]

I agree with the statement in this publication that tyrosine kinase inhibitors (tkis) against the epidermal growth factor receptor (egfr) should be considered [...]

Pseudocirrhosis is a rare form of liver disease that causes clinical symptoms and shows radiographic signs of cirrhosis, but that has histologic features suggesting a distinct pathologic process[...].

Background: Cancer Care Ontario’s Program in Evidence-Based Care (pebc) was formalized in 1997 to produce clinical practice guidelines for cancer management for the Province of Ontario. At the time, the gap between guideline development and implement...

Epithelial ovarian cancer ( EOC) is the leading cause of gynecologic cancer mortality worldwide. [...]

Cytotoxic T lymphocytes (ctls) and natural killer (nk) cells lyse tumours expressing and lacking, respectively, properly conformed class i molecules of the major histocompatibility complex [mhc-i (Figure 1)] [...]

Erlotinib—an oral tyrosine kinase inhibitor (tki) of the epidermal growth factor receptor (egfr)—has commonly been used as a therapeutic option in metastatic non-small-cell lung cancer (nsclc) patients in the second- or third-line treatment setting....